NCT01913301终止2 期
A Randomized Double-Blind, Placebo-Controlled, Multiple-Dose Study to Evaluate the Effects of Alagebrium on Exercise in Subjects With Diastolic Heart Failure
Cardiovascular Clinical Studies0 个研究点目标入组 134 人开始时间: 2007年12月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 134
- 主要终点
- Exercise Tolerance
研究概览
简要总结
The purpose of the study is to gather information regarding the safety and effectiveness of an investigational drug called Alagebrium when used treating Heart Failure in relation to exercise tolerance after 6 months in the trial.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males and females 50 years of age or older.
- •Diagnosis of diabetes OR a diagnosis of hypertension requiring therapy.
- •Echocardiographic ejection fraction ≥ 45% verified within 1 year prior to baseline, assuming no intercurrent cardiac event between the echo and screening.
- •Echocardiographic evidence of diastolic dysfunction as defined by an E/E' ≥ 12 determined within 1 year prior to baseline; sinus rhythm required at time of echo.
- •Previous hospitalization due to heart failure OR a current or previous BNP ≥ 100 pg/mL.
- •New York Heart Association (NYHA) functional class II-IV.
- •At least 1 month between hospitalization for heart failure and randomization.
- •Stable doses of heart failure medications (diuretics, ACE inhibitors, ARB's, beta-adrenergic antagonists, aldosterone antagonists) for at least 1 month prior to randomization.
- •Able to understand content of and willing to provide written informed consent.
- •Agree to use adequate contraception during the study if premenopausal. -
排除标准
- •Ejection fraction < 45%.
- •Screening Six-minute walk test > 450 meters or < 100 meters
- •Clinically significant cardiac valvular disease (mitral regurgitation (MR) > grade I, aortic insufficiency (AI) > grade 1, mitral stenosis (MS), aortic stenosis (AS)).
- •History of stroke, any sequelae of a transient ischemic attack (TIA), or reversible ischemic neurological defect (RIND) within 6 months prior to screening.
- •History of acute myocardial infarction within 6 months prior to screening.
- •Severe COPD as defined by O2 or steroid dependence.
- •History of systemic inflammatory or collagen vascular disease.
- •Active and or treated malignancies within 12 months prior to Visit 1 with the exception of basal cell carcinoma.
- •Any significant systemic illness(es) or medical condition(s) that could lead to difficulty complying with the protocol; or any concurrent condition(s) which, in the investigator's opinion, would prohibit the subject from completing the study, or would not be in the best interest of the subject.
- •Estimated glomerular filtration rate (GFR) ≤ 30 mL/min/1.73m² as calculated by Modification of Diet in Renal Disease (MDRD) study equation [MDRD = 186 X serum creatinine (mg/dl) 1.154 X years -0.203 X (0.742 if female) X (1.210 if African American)].
- •Liver function tests (SGOT and/or SGPT) > 2.5 times the upper limit of normal range.
- •Hb < 10 g/dL.
- •Use of any investigational drug(s) within 30 days prior to screening.
- •Previous exposure to alagebrium.
- •Known seropositivity for HIV or hepatitis C, or presence of hepatitis B surface antigen.
- •Pregnancy or active breast-feeding. Urine pregnancy tests will be performed on all women who are not post-menopausal for at least 1 year.
研究组 & 干预措施
Alagebrium
Experimental
干预措施: Alagebrium (Drug)
结局指标
主要结局
Exercise Tolerance
时间窗: Change from baseline at Week 24
To evaluate the safety and efficacy of alagebrium in subjects diagnosed with diastolic heart failure. The primary variable for assessing efficacy will be assessment of exercise tolerance using the Six-minute walk test.
次要结局
未报告次要终点
研究者
相似试验
撤回
3 期
Study of a Drug [DCVax (tm)-Prostate] to Treat Prostate Cancer When Hormone Therapy is no Longer Effective.Prostate CancerNCT00043212Northwest Biotherapeutics
已完成
2 期
A Study to Evaluate the Efficacy and Safety of Therapeutic Hepatitis B VaccineHepatitis B, ChronicNCT04289987CHA Vaccine Institute Co., Ltd.134
已完成
2 期
A Efficacy Study of PRX-00023 in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)NCT00448292Epix Pharmaceuticals, Inc.330
已完成
1 期
Influenza Vaccine Challenge Study in Healthy SubjectsInfluenzaNCT01226758PepTcell Limited32
已完成
2 期
Efficacy-safety Study of Sublingual Immunotherapy With Depigmented-polymerized Pollen Extracts to Treat RhinoconjunctivitisAllergic RhinoconjunctivitisNCT00550875Laboratorios Leti, S.L.90